Cancer, an intricate and multifaceted disease, is characterized by the uncontrolled proliferation of cells that can lead to serious health complications and ultimately death. Conventional therapeutic strategies mainly target rapidly dividing cancer cells, but often indiscriminately harm healthy cells in the process. As a result, there is a growing interest in exploring novel therapies that are both effective and less toxic to normal cells. Herbs have long been used as natural remedies for various diseases and conditions. Some herbal compounds exhibit potent anti-cancer properties, making them potential candidates for nutraceutical-based treatments. However, despite their promising efficacy, there are considerable limitations in utilizing herbal preparations due to their poor solubility, low bioavailability, rapid metabolism and excretion, as well as potential interference with other medications. Nanotechnology offers a unique platform to overcome these challenges by encapsulating herbal compounds within nanoparticles. This approach not only increases solubility and stability but also enhances the cellular uptake of nutraceuticals, allowing for controlled and targeted delivery of therapeutic agents directly at tumor sites. By harnessing the power of nanotechnology-enabled therapy, this new frontier in cancer treatment presents an opportunity to minimize toxicity while maximizing efficacy. In conclusion, this manuscript provides compelling evidence for integrating nanotechnology with nutraceuticals derived from herbal sources to optimize cancer therapy outcomes. We explore the roadblocks associated with traditional herbal treatments and demonstrate how nanotechnology can help circumvent these issues, paving the way for safer and more effective cancer interventions in future oncological practice.

Amity Institute of Biotechnology Amity University Jharkhand Ranchi Jharkhand India

Chitkara College of Pharmacy Chitkara University Rajpura Punjab India

Department of Biotechnology University Center for Research and Development Chandigarh University Mohali Punjab India

Department of Pharmacology Chameli Devi Institute of Pharmacy Indore Madhya Pradesh India

Faculty of Health Australian Research Centre in Complementary and Integrative Medicine University of Technology Sydney Ultimo NSW Australia

Institute of Advanced Materials IAAM Ulrika Sweden

Laboratory of Animal Immunology and Biotechnology Department of Animal Morphology Physiology and Genetics Faculty of Agri Sciences Mendel University in Brno Zemedelska Brno Czechia

School of Applied and Life Sciences Uttaranchal University Dehradun Uttarakhand India

School of Pharmaceutical Sciences Lovely Professional University Phagwara Punjab India

Zobrazit více v PubMed

Krech R, Peters S, Kroemer H, Fu D, Giuliani R, Sehouli J, et al. . Tobacco cessation and the role of ESMO and medical oncologists: addressing the specific needs of cancer patients in times of the COVID-19 pandemic. ESMO Open. (2023) 8:101579. doi: 10.1016/j.esmoop.2023.101579, PMID: PubMed DOI PMC

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. (2022) 72:7–33. doi: 10.3322/caac.21708, PMID: PubMed DOI

Kabir KMM, Donald WA. Cancer breath testing: a patent review. Expert Opin Ther Pat. (2018) 28:227–39. doi: 10.1080/13543776.2018.1423680, PMID: PubMed DOI

Colli LM, Machiela MJ, Zhang H, Myers TA, Jessop L, Delattre O, et al. . Landscape of combination immunotherapy and targeted therapy to improve cancer management. Cancer Res. (2017) 77:3666–71. doi: 10.1158/0008-5472.CAN-16-3338, PMID: PubMed DOI PMC

Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment. Int J Oncol. (2019) 54:407–19. doi: 10.3892/ijo.2018.4661, PMID: PubMed DOI PMC

Chopra AS, Lordan R, Horbańczuk OK, Atanasov AG, Chopra I, Horbańczuk JO, et al. . The current use and evolving landscape of nutraceuticals. Pharmacol Res. (2022) 175:106001. doi: 10.1016/j.phrs.2021.106001, PMID: PubMed DOI

Sachdeva V, Roy A, Bharadvaja N. Current prospects of nutraceuticals: a review. Curr Pharm Biotechnol. (2020) 21:884–96. doi: 10.2174/1389201021666200130113441 PubMed DOI

Bonam SR, Wu YS, Tunki L, Chellian R, Halmuthur MSK, Muller S, et al. . What has come out from phytomedicines and herbal edibles for the treatment of cancer? ChemMedChem. (2018) 13:1854–72. doi: 10.1002/cmdc.201800343, PMID: PubMed DOI

Puri V, Nagpal M, Singh I, Singh M, Dhingra GA, Huanbutta K, et al. . A comprehensive review on nutraceuticals: therapy support and formulation challenges. Nutrients. (2022) 14:4637. doi: 10.3390/nu14214637, PMID: PubMed DOI PMC

Kaur J, Gulati M, Singh SK, Kuppusamy G, Kapoor B, Mishra V, et al. . Discovering multifaceted role of vanillic acid beyond flavours: Nutraceutical and therapeutic potential. Trends Food Sci Technol. (2022). doi: 10.1016/j.tifs.2022.02.023 DOI

Jadhav P, Kor S, Ahmed S. Application of nanotechnology in formulation of Nutraceuticals In: Kesharwani RK, Rao TJM, Keservani RK, editors. Prebiotics and Probiotics in Disease Regulation and Management. New York, NY: Wiley; (2022). 133–59.

Manocha S, Dhiman S, Grewal AS, Guarve K. Nanotechnology: an approach to overcome bioavailability challenges of nutraceuticals. J Drug Deliv Sci Technol. (2022) 17:103418. doi: 10.1016/j.jddst.2022.103418 DOI

Vishwas S, Gulati M, Kapoor B, Gupta S, Singh SK, Awasthi A, et al. . Expanding the arsenal against Huntington's disease-herbal drugs and their nanoformulations. Curr Neuropharmacol. (2021) 19:957–89. doi: 10.2174/1570159X18666201109090824, PMID: PubMed DOI PMC

Vrânceanu M, Galimberti D, Banc R, Dragoş O, Cozma-Petruţ A, Hegheş SC, et al. . The anticancer potential of plant-derived nutraceuticals via the modulation of gene expression. Plan Theory. (2022) 11:2524. doi: 10.3390/plants11192524, PMID: PubMed DOI PMC

Hejmadi M. Introduction to cancer biology. Copenhagen: Bookboon; (2014).

Roberts TW. The pathology of cancer. J Natl Med Assoc. (1975) 67:368. PMID: PubMed PMC

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. . Signatures of mutational processes in human cancer. Nature. (2013) 500:415–21. doi: 10.1038/nature12477, PMID: PubMed DOI PMC

Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability—an evolving hallmark of cancer. Nat Rev Mol Cell Biol. (2010) 11:220–8. doi: 10.1038/nrm2858, PMID: PubMed DOI

Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. (2009) 458:719–24. doi: 10.1038/nature07943, PMID: PubMed DOI PMC

Mcmanus MT. Micrornas and cancer In: Vincent T, editor. Seminars in cancer biology, vol. 13. Cambridge, MA: Academic Press; (2003). 253–8. PubMed

Carlo M, Croce MD. Oncogenes and cancer. N Engl J Med. (2008) 358:502–11. doi: 10.1056/NEJMra072367 PubMed DOI

Xi R, Hadjipanayis AG, Luquette LJ, Kim TM, Lee E, Zhang J, et al. . Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. Proc Natl Acad Sci. (2011) 108:E1128–36. doi: 10.1073/pnas.1110574108 PubMed DOI PMC

Burdova A, Bouchal J, Tavandzis S, Kolar Z. TMPRSS2-ERG gene fusion in prostate cancer, vol. 158. Olomouc: University in Olomouc; (2014). PubMed

Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep. (2007) 17:1033–6. doi: 10.3892/or.17.5.1033 PMID: PubMed DOI

Pietras K, Östman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. (2010) 316:1324–31. doi: 10.1016/j.yexcr.2010.02.045, PMID: PubMed DOI

Raynaud C, Mallory AC, Latrasse D, Jégu T, Bruggeman Q, Delarue M, et al. . Chromatin meets the cell cycle. J Exp Bot. (2014) 65:2677–89. doi: 10.1093/jxb/ert433, PMID: PubMed DOI

Jeggo PA, Löbrich M. Contribution of DNA repair and cell cycle checkpoint arrest to the maintenance of genomic stability. DNA Repair. (2006) 5:1192–8. doi: 10.1016/j.dnarep.2006.05.011, PMID: PubMed DOI

Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer. (2009) 9:501–7. doi: 10.1038/nrc2663, PMID: PubMed DOI

Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. (2006) 2:213–9. doi: 10.2147/vhrm.2006.2.3.213, PMID: PubMed DOI PMC

Reymond N, d'Água BB, Ridley AJ. Crossing the endothelial barrier during metastasis. Nat Rev Cancer. (2013) 13:858–70. doi: 10.1038/nrc3628, PMID: PubMed DOI

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. (2011) 331:1559–64. doi: 10.1126/science.1203543, PMID: PubMed DOI

Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog. (2013) 18:43–73. doi: 10.1615/critrevoncog.v18.i1-2.40, PMID: PubMed DOI PMC

Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. (2010) 70:5649–69. doi: 10.1158/0008-5472.CAN-10-1040, PMID: PubMed DOI PMC

Chu M, Zheng C, Chen C, Song G, Hu X, Wang ZW. Targeting cancer stem cells by nutraceuticals for cancer therapy In: Chu M, editor. Seminars in cancer biology. Cambridge, MA: Academic Press; (2022) PubMed

Maiuolo J, Gliozzi M, Carresi C, Musolino V, Oppedisano F, Scarano F, et al. . Nutraceuticals and cancer: potential for natural polyphenols. Nutrients. (2021) 13:3834. doi: 10.3390/nu13113834, PMID: PubMed DOI PMC

Chan EWC, Wong CW, Tan YH, Foo JPY, Wong SK, Chan HT. Resveratrol and pterostilbene: a comparative overview of their chemistry, biosynthesis, plant sources and pharmacological properties. J Appl Pharm Sci. (2019) 9:124–9. doi: 10.7324/JAPS.2019.90717 DOI

Horgan XJ, Tatum H, Brannan E, Paull DH, Rhodes LV. Resveratrol analogues surprisingly effective against triple-negative breast cancer, independent of erα. Oncol Rep. (2019) 41:3517–26. doi: 10.3892/or.2019.7122, PMID: PubMed DOI

Fukuda M, Ogasawara Y, Hayashi H, Inoue K, Sakashita H. Resveratrol inhibits proliferation and induces autophagy by blocking SREBP1 expression in Oral cancer cells. Molecules. (2022) 27:8250. doi: 10.3390/molecules27238250, PMID: PubMed DOI PMC

Gadag S, Narayan R, Nayak Y, Garg S, Nayak UY. Design, development and evaluation of resveratrol transdermal patches for breast cancer therapy. Int J Pharm. (2023) 632:122558. doi: 10.1016/j.ijpharm.2022.122558, PMID: PubMed DOI

Wang K, Hou DZ, Ouyang YM, Ling P. Resveratrol enhances paclitaxel- induced apoptosis through oxidative DNA damage in Caco-2 human colon cancer cells. S Afr J Bot. (2023) 157:579–86. doi: 10.1016/j.sajb.2023.04.023 DOI

Xie C, Liang C, Wang R, Yi K, Zhou X, Li X, et al. . Resveratrol suppresses lung cancer by targeting cancer stem-like cells and regulating tumor microenvironment. J Nutr Biochem. (2023) 112:109211. doi: 10.1016/j.jnutbio.2022.109211, PMID: PubMed DOI

Zhang B, Yin X, Sui S. Resveratrol inhibited the progression of human hepatocellular carcinoma by inducing autophagy via regulating p53 and the phosphoinositide 3-kinase/protein kinase B pathway. Oncol Rep. (2018) 40:2758–65. doi: 10.3892/or.2018.6648, PMID: PubMed DOI

Vidoni C, Ferraresi A, Vallino L, Salwa A, Ha JH, Seca C, et al. . Glycolysis inhibition of autophagy drives malignancy in ovarian cancer: exacerbation by IL-6 and attenuation by resveratrol. Int J Mol Sci. (2023) 24:1723. doi: 10.3390/ijms24021723, PMID: PubMed DOI PMC

Hussein HA, Khaphi FL. The apoptotic activity of Curcumin against Oral cancer cells without affecting Normal cells in comparison to paclitaxel activity. Appl Biochem Biotechnol. (2023) 195:5019–33. doi: 10.1007/s12010-023-04454-5 PubMed DOI

Rezaeidian J, Naseh V, Entezari M, Hashemi M. Curcumin- and Piperine- loaded Fe3o4@ Sio2 magnetic nanoparticles: synthesis, characterization, and comparison of the effects on Mcf-7 breast cancer cell line. SSRN Electron J. (2023). doi: 10.2139/ssrn.4329803 DOI

He Q, Liu C, Wang X, Rong K, Zhu M, Duan L, et al. . Exploring the mechanism of curcumin in the treatment of colon cancer based on network pharmacology and molecular docking. Front Pharmacol. (2023) 14:1102581. doi: 10.3389/fphar.2023.1102581, PMID: PubMed DOI PMC

Liu X, Cui H, Li M, Chai Z, Wang H, Jin X, et al. . Tumor killing by a dietary curcumin mono-carbonyl analog that works as a selective ROS generator via trxr inhibition. Eur J Med Chem. (2023) 250:115191. doi: 10.1016/j.ejmech.2023.115191, PMID: PubMed DOI

Hu M, Song HY, Chen L. Quercetin acts via the G3BP1/YWHAZ axis to inhibit glycolysis and proliferation in oral squamous cell carcinoma. Toxicol Mech Methods. (2023) 33:141–50. doi: 10.1080/15376516.2022.2103480, PMID: PubMed DOI

Elsayed AM, Sherif NM, Hassan NS, Althobaiti F, Hanafy NA, Sahyon HA. Novel quercetin encapsulated chitosan functionalized copper oxide nanoparticles as anti-breast cancer agent via regulating p53 in rat model. Int J Biol Macromol. (2021) 185:134–52. doi: 10.1016/j.ijbiomac.2021.06.085, PMID: PubMed DOI

García-Gutiérrez N, Luna-Bárcenas G, Herrera-Hernández G, Campos-Vega R, Lozano- Herrera SJ, Sánchez-Tusié AA, et al. . Quercetin and its fermented extract as a potential inhibitor of Bisphenol A-exposed HT-29 colon cancer cells’ viability. Int J Mol Sci. (2023) 24:5604. doi: 10.3390/ijms24065604, PMID: PubMed DOI PMC

Guan H, Zhang W, Liu H, Jiang Y, Li F, Wu M, et al. . Quercetin induces apoptosis in hepg2 cells via directly interacting with YY1 to disrupt YY1-p53 interaction. Meta. (2023) 13:229. doi: 10.3390/metabo13020229, PMID: PubMed DOI PMC

Teekaraman D, Elayapillai SP, Viswanathan MP, Jagadeesan A. Quercetin inhibits human metastatic ovarian cancer cell growth and modulates components of the intrinsic apoptotic pathway in PA-1 cell line. Chem Biol Interact. (2019) 300:91–100. doi: 10.1016/j.cbi.2019.01.008 PubMed DOI

Zada S, Hwang JS, Ahmed M, Lai TH, Pham TM, Kim DH, et al. . Protein kinase a activation by β-Lapachone is associated with apoptotic cell death in NQO1-overexpressing breast cancer cells. Oncol Rep. (2019) 42:1621–30. doi: 10.3892/or.2019.7243, PMID: PubMed DOI

Zhao W, Jiang L, Fang T, Fang F, Liu Y, Zhao Y, et al. . Β-Lapachone selectively kills hepatocellular carcinoma cells by targeting NQO1 to induce extensive DNA damage and PARP1 Hyperactivation. Front Oncol. (2021) 11:747282. doi: 10.3389/fonc.2021.726018, PMID: PubMed DOI PMC

Yu HY, Kim SO, Jin CY, Kim GY, Kim WJ, Yoo YH, et al. . β-Lapachone-induced apoptosis of human gastric carcinoma AGS cells is caspase-dependent and regulated by the PI3K/Akt pathway. Biomol Ther (Seoul). (2014) 22:184–92. doi: 10.4062/biomolther.2014.026 PubMed DOI PMC

Qadir MI, Iqbal MS, Khan R. Β-lapachone: a promising anticancer agent with a unique NQO1 specific apoptosis in pancreatic cancer. Curr Cancer Drug Targets. (2022) 22:537–40. doi: 10.2174/1568009622666220427121127, PMID: PubMed DOI

Kon M, Ishikawa T, Ohashi Y, Yamada H, Ogasawara M. Epigallocatechin gallate stimulated histamine production and downregulated histamine H1 receptor in oral cancer cell lines expressing histidine decarboxylase. J Oral Biosci. (2022) 64:120–30. doi: 10.1016/j.job.2022.01.003, PMID: PubMed DOI

Zan L, Chen Q, Zhang L, Li X. Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of mir-25. Bioengineered. (2019) 10:374–82. doi: 10.1080/21655979.2019.1657327, PMID: PubMed DOI PMC

Mayer BF, Stagno MJ, Fuchs J, Warmann SW, Schmid E. Epigallocatechin Gallate inhibits cell growth and hedgehog Signalling in human Rhabdomyosarcoma cell lines. Anticancer Res. (2023) 43:1025–30. doi: 10.21873/anticanres.16247, PMID: PubMed DOI

Khiewkamrop P, Surangkul D, Srikummool M, Richert L, Pekthong D, Parhira S, et al. . Epigallocatechin gallate triggers apoptosis by suppressing de novo lipogenesis in colorectal carcinoma cells. FEBS Open Bio. (2022) 12:937. doi: 10.1002/2211-5463.13391, PMID: PubMed DOI PMC

Mostafa-Hedeab G, Hassan ME, Halawa TF. Epigallocatechin gallate ameliorates tetrahydrochloride-induced liver toxicity in rats via inhibition of tgfβ/p-ERK/p- Smad1/2 signaling, antioxidant, anti-inflammatory activity. Saudi Pharm J. (2022) 30:1293–300. doi: 10.1016/j.jsps.2022.06.021, PMID: PubMed DOI PMC

Yousuf M, Shamsi A, Khan P, Shahbaaz M, MF AA, Hussain A, et al. . Ellagic acid controls cell proliferation and induces apoptosis in breast cancer cells via inhibition of cyclin-dependent kinase 6. Int J Mol Sci. (2020) 21:3526. doi: 10.3390/ijms21103526 PubMed DOI PMC

Duan J, Zhan JC, Wang GZ, Zhao XC, Huang WD, Zhou GB. The red wine component ellagic acid induces autophagy and exhibits anti-lung cancer activity in vitro and in vivo. J Cell Mol Med. (2019) 23:143–54. doi: 10.1111/jcmm.13899, PMID: PubMed DOI PMC

Zhang C, Hu J, Sheng L, Yuan M, Wu Y, Chen L, et al. . Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway. Food Funct. (2019) 10:3410–20. doi: 10.1039/c9fo00284g PubMed DOI

Mohammed Saleem YI, Selim MI. MDM2 as a target for ellagic acid-mediated suppression of prostate cancer cells in vitro. Oncol Rep. (2020) 44:1255–65. doi: 10.3892/or.2020.7664, PMID: PubMed DOI

Cheshomi H, Bahrami AR, Rafatpanah H, Matin MM. The effects of ellagic acid and other pomegranate (Punica granatum L.) derivatives on human gastric cancer AGS cells. Hum Exp Toxicol. (2022) 41:09603271211064534. doi: 10.1177/09603271211064534 PubMed DOI

Medeiros PSC, De Carvalho AB, Ruano C, Otero JC, Marques MPM. Raman microspectroscopy for probing the impact of a dietary antioxidant on human breast cancer cells. Food Funct. (2016) 7:2800–10. doi: 10.1039/C6FO00209A, PMID: PubMed DOI

Sivoňová MK, Kaplán P, Tatarková Z, Lichardusová L, Dušenka R, Jurečeková J. Androgen receptor and soy isoflavones in prostate cancer. Mol Clin Oncol. (2019) 10:191–204. doi: 10.3892/mco.2018.1792, PMID: PubMed DOI PMC

Liu H, Wang X, Jin O, Fu D, Peng Y, Cheng C, et al. . Effect of Daidzein on the proliferation of lung cancer cells involved in the apoptotic signaling pathway. Res Squ. (2020). doi: 10.21203/rs.3.rs-127789/v1 DOI

Hua F, Li CH, Chen XG, Liu XP. Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells by inducing apoptosis and cell cycle arrest, and inhibiting the Raf/MEK/ERK cascade retraction in/10.3892/ijmm. 2021.4929. Int J Mol Med. (2018) 41:3485–92. doi: 10.3892/ijmm.2018.3531, PMID: PubMed DOI

Yuan B, Liao F, Shi ZZ, Ren Y, Deng XL, Yang TT, et al. . Dihydroartemisinin inhibits the proliferation, colony formation and induces ferroptosis of lung cancer cells by inhibiting PRIM2/SLC7A11 axis. Onco Targets Ther. (2020) 13:10829–40. doi: 10.2147/OTT.S248492 PubMed DOI PMC

Wang Z, Li M, Liu Y, Qiao Z, Bai T, Yang L, et al. . Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response-induced upregulation of CHAC1 expression. Oncol Rep. (2021) 46:240. doi: 10.3892/or.2021.8191 PubMed DOI PMC

Paccez JD, Duncan K, Sekar D, Correa RG, Wang Y, Gu X, et al. . Dihydroartemisinin inhibits prostate cancer via JARID2/mir-7/mir-34a-dependent downregulation of Axl. Oncogenesis. (2019) 8:14. doi: 10.1038/s41389-019-0122-6 PubMed DOI PMC

Wang T, Luo R, Li W, Yan H, Xie S, Xiao W, et al. . Dihydroartemisinin suppresses bladder cancer cell invasion and migration by regulating KDM3A and p21. J Cancer. (2020) 11:1115–24. doi: 10.7150/jca.36174 PubMed DOI PMC

Kuo CS, Yang CY, Lin CK, Lin GJ, Sytwu HK, Chen YW. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-gamma-modulated microenvironment in vitro, in vivo, and in clinical patients. Biomed Pharmacother. (2021) 133:111057. doi: 10.1016/j.biopha.2020.111057 PubMed DOI

Jiang W, Chen M, Xiao C, Yang W, Qin Q, Tan Q, et al. . Triptolide suppresses growth of breast cancer by targeting HMGB1 in vitro and in vivo. Biol Pharm Bull. (2019) 42:892–9. doi: 10.1248/bpb.b18-00818, PMID: PubMed DOI

Yanchun M, Yi W, Lu W, Yu Q, Jian Y, Pengzhou K, et al. . Triptolide prevents proliferation and migration of esophageal squamous cell cancer via MAPK/ERK signaling pathway. Eur J Pharmacol. (2019) 851:43–51. doi: 10.1016/j.ejphar.2019.02.030 PubMed DOI

Acikgoz E, Tatar C, Oktem G. Triptolide inhibits CD133+/CD44+ colon cancer stem cell growth and migration through triggering apoptosis and represses epithelial-mesenchymal transition via downregulating expressions of snail, slug, and twist. J Cell Biochem. (2020) 121:3313–24. doi: 10.1002/jcb.29602, PMID: PubMed DOI

Song JM, Molla K, Anandharaj A, Cornax I, Osullivan MG, Kirtane AR, et al. . Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling. Oncotarget. (2017) 8:26927. doi: 10.18632/oncotarget.15879, PMID: PubMed DOI PMC

Huang W, He T, Chai C, Yang Y, Zheng Y, Zhou P, et al. . Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS One. (2012) 7:e37693. doi: 10.1371/journal.pone.0037693, PMID: PubMed DOI PMC

Yu Y, Xing Y, Zhang Q, Zhang Q, Huang S, Li X, et al. . Soy isoflavone genistein inhibits hsa_circ_0031250/mir-873-5p/FOXM1 axis to suppress non-small-cell lung cancer progression. IUBMB Life. (2021) 73:92–107. doi: 10.1002/iub.2404, PMID: PubMed DOI

Zhang Q, Bao J, Yang J. Genistein-triggered anticancer activity against liver cancer cell line hepg2 involves ROS generation, mitochondrial apoptosis, G2/M cell cycle arrest and inhibition of cell migration and inhibition of cell migration. Arch Med Sci. (2019) 15:1001–9. doi: 10.5114/aoms.2018.78742 PubMed DOI PMC

Almatroodi SA, Alsahli MA, Almatroudi A, Rahmani AH. Garlic and its active compounds: a potential candidate in the prevention of cancer by modulating various cell signalling pathways. Anti Cancer Agents Med Chem. (2019) 19:1314–24. doi: 10.2174/1871520619666190409100955 PubMed DOI

Wang G, Hu Z, Song X, Cui Q, Fu Q, Jia R, et al. . Analgesic and anti- inflammatory activities of resveratrol through classic models in mice and rats. Evid Based Complement Alternat Med. (2017) 2017:5197567. doi: 10.1155/2017/5197567 PubMed DOI PMC

Wang N, Wang Q, Tang H, Zhang F, Zheng Y, Wang S, et al. . Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells. J Exp Clin Cancer Res. (2017) 36:172. doi: 10.1186/s13046-017-0635-9 PubMed DOI PMC

Chen J, Cao X, Cui Y, Zeng G, Chen J, Zhang G. Resveratrol alleviates lysophosphatidylcholine-induced damage and inflammation in vascular endothelial cells. Mol Med Rep. (2018) 17:4011–8. doi: 10.3892/mmr.2017.8300, PMID: PubMed DOI

Varoni EM, Lo Faro AF, Sharifi-Rad J, Iriti M. Anticancer molecular mechanisms of resveratrol. Front Nutr. (2016) 3:8. doi: 10.3389/fnut.2016.00008, PMID: PubMed DOI PMC

Singh SK, Banerjee S, Acosta EP, Lillard JW, Singh R. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/p21waf1/CIP1 and p27kip1 pathway. Oncotarget. (2017) 8:17216. doi: 10.18632/oncotarget.15303, PMID: PubMed DOI PMC

Farooqui T, Farooqui AA. Curcumin: historical background, chemistry, pharmacological action, and potential therapeutic value. Curcumin Neurol Psychiat Disord. (2019) 2019:23–44. doi: 10.1016/B978-0-12-815461-8.00002-5 DOI

Gupta AP, Khan S, Manzoor MM, Yadav AK, Sharma G, Anand R, et al. . Anticancer curcumin: natural analogues and structure-activity relationship. Stud Nat Prod Chem. (2017) 54:355–401. doi: 10.1016/B978-0-444-63929-5.00010-3 DOI

Gali-Muhtasib H, Hmadi R, Kareh M, Tohme R, Darwiche N. Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis. Apoptosis. (2015) 20:1531–62. doi: 10.1007/s10495-015-1169-2, PMID: PubMed DOI

Aljelehawy Q, Mal Allah OR, Sourazur G. Physicochemical properties, medicinal chemistry, toxicity, and absorption of quercetin and its interaction with spike glycoprotein of SARS-cov-2: molecular docking. Nano Micro Biosys. (2022) 1:32–9. doi: 10.22034/NMBJ.2022.163207 DOI

Cao G, Sofic E, Prior RL. Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free Radic Biol Med. (1997) 22:749–60. doi: 10.1016/S0891-5849(96)00351-6, PMID: PubMed DOI

Jana N, Břetislav G, Pavel S, Pavla U. Potential of the flavonoid quercetin to prevent and treat cancer-current status of research. Klin Onkol. (2018) 31:184–90. doi: 10.14735/amko2018184, PMID: PubMed DOI

Almatroodi SA, Alsahli MA, Almatroudi A, Verma AK, Aloliqi A, Allemailem KS, et al. . Potential therapeutic targets of quercetin, a plant flavonol, and its role in the therapy of various types of cancer through the modulation of various cell signaling pathways. Molecules. (2021) 26:1315. doi: 10.3390/molecules26051315, PMID: PubMed DOI PMC

Granato M, Rizzello C, Montani MSG, Cuomo L, Vitillo M, Santarelli R, et al. . Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mtor and STAT3 signaling pathways. J Nutr Biochem. (2017) 41:124–36. doi: 10.1016/j.jnutbio.2016.12.011, PMID: PubMed DOI

Salas C, Tapia RA, Ciudad K, Armstrong V, Orellana M, Kemmerling U, et al. . Trypanosoma cruzi: activities of lapachol and α-and β-lapachone derivatives against epimastigote and trypomastigote forms. Bioorg Med Chem. (2008) 16:668–74. doi: 10.1016/j.bmc.2007.10.038, PMID: PubMed DOI

Gong Q, Hu J, Wang P, Li X, Zhang X. A comprehensive review on β- lapachone: mechanisms, structural modifications, and therapeutic potentials. Eur J Med Chem. (2021) 210:112962. doi: 10.1016/j.ejmech.2020.112962, PMID: PubMed DOI

Ferraz da Costa DC, Pereira Rangel L, Martins-Dinis MMDDC, Ferretti GDDS, Ferreira VF, Silva JL. Anticancer potential of resveratrol, β-lapachone and their analogues. Molecules. (2020) 25:893. doi: 10.3390/molecules25040893, PMID: PubMed DOI PMC

Schramm L. Going green: the role of the green tea component EGCG in chemoprevention. J Carcinog Mutagen. (2013) 4:1000142. doi: 10.4172/2157-2518.1000142, PMID: PubMed DOI PMC

Khandelwal A, Hall JA, Blagg BS. Synthesis and structure–activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor. J Org Chem. (2013) 78:7859–84. doi: 10.1021/jo401027r, PMID: PubMed DOI PMC

Landis-Piwowar KR, Kuhn DJ, Wan SB, Chen D, Chan TH, Dou QP. Evaluation of proteasome-inhibitory and apoptosis-inducing potencies of novel (−)-EGCG analogs and their prodrugs. Int J Mol Med. (2005) 15:735–42. doi: 10.3892/ijmm.15.4.735 PMID: PubMed DOI

Gan RY, Li HB, Sui ZQ, Corke H. Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): an updated review. Crit Rev Food Sci Nutr. (2018) 58:924–41. doi: 10.1080/10408398.2016.1231168 PubMed DOI

Granja A, Frias I, Neves AR, Pinheiro M, Reis S. Therapeutic potential of epigallocatechin gallate nanodelivery systems. Biomed Res Int. (2017) 2017:5813793. doi: 10.1155/2017/5813793 PubMed DOI PMC

Derosa G, Maffioli P, Sahebkar A. Ellagic acid and its role in chronic diseases. Adv Exp Med Biol. (2016) 928:473–9. doi: 10.1007/978-3-319-41334-1_20 PubMed DOI

Evtyugin DD, Magina S, Evtuguin DV. Recent advances in the production and applications of ellagic acid and its derivatives. A review. Molecules. (2020) 25:2745. doi: 10.3390/molecules25122745, PMID: PubMed DOI PMC

Baradaran Rahimi V, Ghadiri M, Ramezani M, Askari VR. Antiinflammatory and anti-cancer activities of pomegranate and its constituent, ellagic acid: evidence from cellular, animal, and clinical studies. Phytother Res. (2020) 34:685–720. doi: 10.1002/ptr.6565, PMID: PubMed DOI

Rawat S, Pathak S, Gupta G, Singh SK, Singh H, Mishra A, et al. . Recent updates on daidzein against oxidative stress and cancer. EXCLI J. (2019) 18:950. doi: 10.17179/excli2019-1847, PMID: PubMed DOI PMC

Alshehri MM, Sharifi-Rad J, Herrera-Bravo J, Jara EL, Salazar LA, Kregiel D, et al. . Therapeutic potential of isoflavones with an emphasis on daidzein. Oxidative Med Cell Longev. (2021) 2021:6331630. doi: 10.1155/2021/6331630, PMID: PubMed DOI PMC

Li WD, Dong YJ, Tu YY, Lin ZB. Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation. Int Immunopharmacol. (2006) 6:1243–50. doi: 10.1016/j.intimp.2006.03.004, PMID: PubMed DOI

Dai X, Zhang X, Chen W, Chen Y, Zhang Q, Mo S, et al. . Dihydroartemisinin: a potential natural anticancer drug. Int J Biol Sci. (2021) 17:603. doi: 10.7150/ijbs.50364, PMID: PubMed DOI PMC

Chen YZ, Gao Q, Zhao XZ, Chen XM, Zhang F, Chen J, et al. . Meta-analysis of Tripterygium wilfordii hook F in the immunosuppressive treatment of IgA nephropathy. Intern Med. (2010) 49:2049–55. doi: 10.2169/internalmedicine.49.3704, PMID: PubMed DOI

Aoyagi Y, Hitotsuyanagi Y, Hasuda T, Fukaya H, Takeya K, Aiyama R, et al. . Semisynthesis of C-ring modified triptolide analogues and their cytotoxic activities. Bioorg Med Chem Lett. (2006) 16:1947–9. doi: 10.1016/j.bmcl.2005.12.098, PMID: PubMed DOI

Li Z, Zhou ZL, Miao ZH, Lin LP, Feng HJ, Tong LJ, et al. . Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents. J Med Chem. (2009) 52:5115–23. doi: 10.1021/jm900342g PubMed DOI

Noel P, Von Hoff DD, Saluja AK, Velagapudi M, Borazanci E, Han H. Triptolide and its derivatives as cancer therapies. Trends Pharmacol Sci. (2019) 40:327–41. doi: 10.1016/j.tips.2019.03.002, PMID: PubMed DOI

Zaheer K, Humayoun Akhtar M. An updated review of dietary isoflavones: nutrition, processing, bioavailability and impacts on human health. Crit Rev Food Sci Nutr. (2017) 57:1280–93. doi: 10.1080/10408398.2014.989958 PubMed DOI

Ronis MJ. Effects of soy containing diet and isoflavones on cytochrome P450 enzyme expression and activity. Drug Metab Rev. (2016) 48:331–41. doi: 10.1080/03602532.2016.1206562, PMID: PubMed DOI PMC

Sharifi-Rad J, Quispe C, Imran M, Rauf A, Nadeem M, Gondal TA, et al. . Genistein: an integrative overview of its mode of action, pharmacological properties, and health benefits. Oxidative Med Cell Longev. (2021) 2021:3268136. doi: 10.1155/2021/3268136, PMID: PubMed DOI PMC

Bigbee W, Herberman RB. Tumor markers and immunodiagnosis In: Kufe DW, Pollock RE, Weichselbaum RR, editors. Holland-Frei Cancer Medicine. Hamilton, ON: BC Decker; (2003)

Andriole GL, Crawford ED, Grubb RL, III, Buys SS, Chia D, Church TR, et al. . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. (2009) 360:1310–9. doi: 10.1056/NEJMoa0810696, PMID: PubMed DOI PMC

Sethi S, Ali S, Philip PA, Sarkar FH. Clinical advances in molecular biomarkers for cancer diagnosis and therapy. Int J Mol Sci. (2013) 14:14771–84. doi: 10.3390/ijms140714771, PMID: PubMed DOI PMC

Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights. (2006) 1:117727190600100001. PubMed PMC

Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. (1965) 122:467–81. doi: 10.1084/jem.122.3.467, PMID: PubMed DOI PMC

Hammarström S, Engvall E, Johansson BG, Svensson S, Sundblad G, Goldstein IJ. Nature of the tumor-associated determinant (s) of carcinoembryonic antigen. Proc Natl Acad Sci. (1975) 72:1528–32. doi: 10.1073/pnas.72.4.1528, PMID: PubMed DOI PMC

Krupey J, Wilson T, Freedman SO, Gold P. The preparation of purified carcinoembryonic antigen of the human digestive system from large quantities of tumor tissue. Immunochemistry. (1972) 9:617–22. doi: 10.1016/0019-2791(72)90247-9, PMID: PubMed DOI

Pritchard DG, Egan ML. Isolation of carcinoembryonic antigen by an improved procedure. Immunochemistry. (1978) 15:385–7. doi: 10.1016/0161-5890(78)90135-9 PubMed DOI

Westwood JH, Bessell EM, Bukhari MA, Thomas P, Walker JM. Studies on the structure of the carcinoembryonic antigen—I. Some deductions on the basis of chemical degradations. Immunochemistry. (1974) 11:811–8. doi: 10.1016/0019-2791(74)90302-4, PMID: PubMed DOI

Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg. (1998) 228:59. doi: 10.1097/00000658-199807000-00009, PMID: PubMed DOI PMC

Bajenova OV, Zimmer R, Stolper E, Salisbury-Rowswell J, Nanji A, Thomas P. Heterogeneous RNA-binding protein M4 is a receptor for carcinoembryonic antigen in Kupffer cells. J Biol Chem. (2001) 276:31067–73. doi: 10.1074/jbc.M104093200, PMID: PubMed DOI

Bajenova O, Stolper E, Gapon S, Sundina N, Zimmer R, Thomas P. Surface expression of heterogeneous nuclear RNA binding protein M4 on Kupffer cell relates to its function as a carcinoembryonic antigen receptor. Exp Cell Res. (2003) 291:228–41. doi: 10.1016/S0014-4827(03)00373-2, PMID: PubMed DOI

Edmiston KH, Gangopadhyay A, Shoji Y, Nachman AP, Thomas P, Jessup JM. In vivo induction of murine cytokine production by carcinoembryonic antigen. Cancer Res. (1997) 57:4432–6. PMID: PubMed

Gangopadhyay A, Bajenova O, Kelly TM, Thomas P. Carcinoembryonic antigen induces cytokine expression in Kupffer cells: implications for hepatic metastasis from colorectal cancer. Cancer Res. (1996) 56:4805–10. PMID: PubMed

Jessup JM, Battle P, Waller H, Edmiston KH, Stolz DB, Watkins SC, et al. . Reactive nitrogen and oxygen radicals formed during hepatic ischemia- reperfusion kill weakly metastatic colorectal cancer cells. Cancer Res. (1999) 59:1825–9. PMID: PubMed

Thomas P, Hayashi H, Zimmer R, Forse RA. Regulation of cytokine production in carcinoembryonic antigen stimulated Kupffer cells by β-2 adrenergic receptors: implications for hepatic metastasis. Cancer Lett. (2004) 209:251–7. doi: 10.1016/j.canlet.2003.12.027, PMID: PubMed DOI

Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. (1962) 237:1555–62. doi: 10.1016/S0021-9258(19)83739-0, PMID: PubMed DOI

Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol. (1965) 12:394–407. doi: 10.1016/0012-1606(65)90005-9 PubMed DOI

Carpenter G, King L, Jr, Cohen S. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature. (1978) 276:409–10. doi: 10.1038/276409a0, PMID: PubMed DOI

Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. . The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. (1984) 312:513–6. doi: 10.1038/312513a0, PMID: PubMed DOI

Hynes NE, Stern DF. The biology of erbb-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta Rev Cancer. (1994) 1198:165–84. doi: 10.1016/0304-419x(94)90012-4 PubMed DOI

Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. (2013) 13:663–73. doi: 10.1038/nrc3559, PMID: PubMed DOI

Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. (2009) 9:463–75. doi: 10.1038/nrc2656, PMID: PubMed DOI

Carraway KL, III, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, et al. . Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature. (1997) 387:512–6. doi: 10.1038/387512a0, PMID: PubMed DOI

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. (1987) 235:177–82. doi: 10.1126/science.3798106, PMID: PubMed DOI

Giordano SH, Franzoi MAB, Temin S, Anders CK, Chandarlapaty S, Crews JR, et al. . Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. (2022) 40:2612–35. doi: 10.1200/JCO.22.00519 PubMed DOI

Bast RC, Jr, Klug TL, John ES, Jenison E, Niloff JM, Lazarus H, et al. . A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. (1983) 309:883–7. doi: 10.1056/NEJM198310133091503, PMID: PubMed DOI

Bast RC, Feeney M, Lazarus HERBERT, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. (1981) 68:1331–7. doi: 10.1172/JCI110380, PMID: PubMed DOI PMC

Scholler N, Urban N. CA125 in ovarian cancer. Biomark Med. (2007) 1:513–23. doi: 10.2217/17520363.1.4.513 PubMed DOI PMC

Sharma S. Tumor markers in clinical practice: General principles and guidelines. Indian J Med Paediatr Oncol. (2009) 30:1–8. doi: 10.4103/0971-5851.56328 PubMed DOI PMC

Diamandis EP. ed. Tumor markers: Physiology, pathobiology, technology, and clinical applications. Washington DC: Amer. Assoc. for Clinical Chemistry; (2002).

Hamd-Ghadareh S, Salimi A, Fathi F, Bahrami S. An amplified comparative fluorescence resonance energy transfer immunosensing of CA125 tumor marker and ovarian cancer cells using green and economic carbon dots for bio-applications in labeling, imaging and sensing. Biosens Bioelectron. (2017) 96:308–16. doi: 10.1016/j.bios.2017.05.003, PMID: PubMed DOI

Zhang L, Chen Y, Wang K. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer. (2019) 43:135–44. doi: 10.1016/j.currproblcancer.2018.06.001, PMID: PubMed DOI

Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol. (2015) 10:473–510. doi: 10.1146/annurev-pathol-012414-040438, PMID: PubMed DOI PMC

Bao L, Loda M, Zetter BR. Thymosin β15 expression in tumor cell lines with varying metastatic potential. Clin Exp Metastasis. (1998) 16:227–33. doi: 10.1023/A:1006540824969, PMID: PubMed DOI

Diamandis EP. Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem. (2003) 49:1272–5. doi: 10.1373/49.8.1272, PMID: PubMed DOI

Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. . ONCOMINE: a cancer microarray database and integrated data- mining platform. Neoplasia. (2004) 6:1–6. doi: 10.1016/S1476-5586(04)80047-2, PMID: PubMed DOI PMC

Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, et al. . Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol. (2004) 171:626–30. doi: 10.1097/01.ju.0000107826.78479.90, PMID: PubMed DOI

Wang Y, Wu MC, Sham JS, Zhang W, Wu WQ, Guan XY. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma: a broad survey using high-throughput tissue microarray. Cancer. (2002) 95:2346–52. doi: 10.1002/cncr.10963, PMID: PubMed DOI

Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol. (2001) 165:600–11. doi: 10.1097/00005392-200102000-00081 PubMed DOI

Mungan NA, Vriesema JLJ, Thomas CMG, Kiemeney LALM, Witjes JA. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer. Urology. (2000) 56:787–91. doi: 10.1016/S0090-4295(00)00798-6, PMID: PubMed DOI

Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, et al. . Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. (2010) 70:7392–9. doi: 10.1158/0008-5472.CAN-10-2027, PMID: PubMed DOI PMC

Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, et al. . Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases—safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res. (2011) 4:1419–25. doi: 10.1158/1940-6207.CAPR-11-0148, PMID: PubMed DOI PMC

Zhu W, Qin W, Zhang K, Rottinghaus GE, Chen YC, Kliethermes B, et al. . Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr Cancer. (2012) 64:393–400. doi: 10.1080/01635581.2012.654926, PMID: PubMed DOI PMC

Singh CK, Chhabra G, Ndiaye MA, Siddiqui IA, Panackal JE, Mintie CA, et al. . Quercetin–resveratrol combination for prostate cancer management in TRAMP mice. Cancers. (2020) 12:2141. doi: 10.3390/cancers12082141, PMID: PubMed DOI PMC

Khan K, Quispe C, Javed Z, Iqbal MJ, Sadia H, Raza S, et al. . Resveratrol, curcumin, paclitaxel and mirnas mediated regulation of PI3K/Akt/mtor pathway: go four better to treat bladder cancer. Cancer Cell Int. (2020) 20:560. doi: 10.1186/s12935-020-01660-7 PubMed DOI PMC

Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-κb and upregulation of TRAIL receptors. Cancer Res. (2009) 69:8958–66. doi: 10.1158/0008-5472.CAN-09-2045, PMID: PubMed DOI

Barve A, Khor TO, Hao X, Keum YS, Yang CS, Reddy B, et al. . Murine prostate cancer inhibition by dietary phytochemicals—curcumin and phenyethylisothiocyanate. Pharm Res. (2008) 25:2181–9. doi: 10.1007/s11095-008-9574-7, PMID: PubMed DOI PMC

Cao L, Yang Y, Ye Z, Lin B, Zeng J, Li C, et al. . Quercetin-3-methyl ether suppresses human breast cancer stem cell formation by inhibiting the Notch1 and PI3K/Akt signaling pathways. Int J Mol Med. (2018) 42:1625–36. doi: 10.3892/ijmm.2018.3741, PMID: PubMed DOI

Abdu S, Juaid N, Amin A, Moulay M, Miled N. Effects of sorafenib and quercetin alone or in combination in treating hepatocellular carcinoma: in vitro and in vivo approaches. Molecules. (2022) 27. doi: 10.3390/molecules27228082, PMID: PubMed DOI PMC

Aalinkeel R, Bindukumar B, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC, et al. . The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate. (2008) 68:1773–89. doi: 10.1002/pros.20845, PMID: PubMed DOI PMC

Hong Y, Lee J, Moon H, Ryu CH, Seok J, Jung YS, et al. . Quercetin induces anticancer activity by upregulating pro-NAG-1/GDF15 in differentiated thyroid cancer cells. Cancers. (2021) 13:3022. doi: 10.3390/cancers13123022, PMID: PubMed DOI PMC

Yang Y, Zhou X, Xu M, Piao J, Zhang Y, Lin Z, et al. . Β-lapachone suppresses tumour progression by inhibiting epithelial-to-mesenchymal transition in NQO1-positive breast cancers. Sci Rep. (2017) 7:2681. doi: 10.1038/s41598-017-02937-0 PubMed DOI PMC

Silvers MA, Deja S, Singh N, Egnatchik RA, Sudderth J, Luo X, et al. . The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. J Biol Chem. (2017) 292:18203–16. doi: 10.1074/jbc.M117.813923, PMID: PubMed DOI PMC

Thangapazham RL, Passi N, Maheshwari RK. Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells. Cancer Biol Ther. (2007) 6:1938–43. doi: 10.4161/cbt.6.12.4974 PubMed DOI

Huang CY, Han Z, Li X, Xie HH, Zhu SS. Mechanism of EGCG promoting apoptosis of MCF-7 cell line in human breast cancer. Oncol Lett. (2017) 14:3623–7. doi: 10.3892/ol.2017.6641, PMID: PubMed DOI PMC

Sojoodi M, Wei L, Erstad DJ, Yamada S, Fujii T, Hirschfield H, et al. . Epigallocatechin gallate induces hepatic stellate cell senescence and attenuates development of hepatocellular carcinoma. Cancer Prev Res. (2020) 13:497–508. doi: 10.1158/1940-6207.CAPR-19-0383, PMID: PubMed DOI PMC

Piwowarczyk L, Stawny M, Mlynarczyk DT, Muszalska-Kolos I, Goslinski T, Jelińska A. Role of curcumin and (−)-Epigallocatechin-3-O-gallate in bladder cancer treatment: a review. Cancers. (2020) 12:1801. doi: 10.3390/cancers12071801, PMID: PubMed DOI PMC

Sah DK, Khoi PN, Li S, Arjunan A, Jeong JU, Jung YD. (−)-Epigallocatechin-3-Gallate prevents IL-1β-induced upar expression and invasiveness via the suppression of NF-κb and AP-1 in human bladder cancer cells. Int J Mol Sci. (2022) 23:14008. doi: 10.3390/ijms232214008, PMID: PubMed DOI PMC

Zhong Y, Chiou YS, Pan MH, Ho CT, Shahidi F. Protective effects of epigallocatechin gallate (EGCG) derivatives on azoxymethane-induced colonic carcinogenesis in mice. J Funct Foods. (2012) 4:323–30. doi: 10.1016/j.jff.2011.12.011, PMID: PubMed DOI

Zaazaa AM, Lokman MS, Shalby AB, Ahmed HH, El-Toumy SA. Ellagic acid holds promise against hepatocellular carcinoma in an experimental model: mechanisms of action. Asian Pac J Cancer Prev. (2018) 19:387. doi: 10.22034/APJCP.2018.19.2.387, PMID: PubMed DOI PMC

Oghumu S, Casto BC, Ahn-Jarvis J, Weghorst LC, Maloney J, Geuy P, et al. . Inhibition of pro-inflammatory and anti-apoptotic biomarkers during experimental oral cancer chemoprevention by dietary black raspberries. Front Immunol. (2017) 8:1325. doi: 10.3389/fimmu.2017.01325 PubMed DOI PMC

Choi EJ, Kim GH. Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells. Phytomedicine. (2008) 15:683–90. doi: 10.1016/j.phymed.2008.04.006, PMID: PubMed DOI

Chen Y, Mi Y, Zhang X, Ma Q, Song Y, Zhang L, et al. . Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells. J Exp Clin Cancer Res. (2019) 38:402. doi: 10.1186/s13046-019-1413-7 PubMed DOI PMC

Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, Chen G, et al. . Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol. (2010) 80:22–30. doi: 10.1016/j.bcp.2010.02.016, PMID: PubMed DOI

Wu L, Cheng Y, Deng J, Tao W, Ye J. Dihydroartemisinin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cell by upregulating tumor necrosis factor via JNK/NF-κb pathways. Evid Based Complement Alternat Med. (2019) 2019:9581327. doi: 10.1155/2019/9581327 PubMed DOI PMC

Li X, Ba Q, Liu Y, Yue Q, Chen P, Li J, et al. . Dihydroartemisinin selectively inhibits pdgfrα-positive ovarian cancer growth and metastasis through inducing degradation of pdgfrα protein. Cell Discov. (2017) 3:17042. doi: 10.1038/celldisc.2017.42 PubMed DOI PMC

Qiu H, Zhang X, Yu H, Gao R, Shi J, Shen T. Identification of potential targets of triptolide in regulating the tumor microenvironment of stomach adenocarcinoma patients using bioinformatics. Bioengineered. (2021) 12:4304–19. doi: 10.1080/21655979.2021.1945522, PMID: PubMed DOI PMC

Kim ST, Kim SY, Lee J, Kim K, Park SH, Park YS, et al. . Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. BMC Cancer. (2018) 18:1103. doi: 10.1186/s12885-018-4995-0 PubMed DOI PMC

Avci CB, Susluer SY, Caglar HO, Balci T, Aygunes D, Dodurga Y, et al. . Genistein-induced mir-23b expression inhibits the growth of breast cancer cells. Contemp Oncol. (2015) 19:32–5. doi: 10.5114/wo.2014.44121 PubMed DOI PMC

Chen X, Wu Y, Gu J, Liang P, Shen M, Xi J, et al. . Anti-invasive effect and pharmacological mechanism of genistein against colorectal cancer. Biofactors. (2020) 46:620–8. doi: 10.1002/biof.1627, PMID: PubMed DOI

Sahin K, Yenice E, Bilir B, Orhan C, Tuzcu M, Sahin N, et al. . Genistein prevents development of spontaneous ovarian cancer and inhibits tumor growth in hen model. Cancer Prev Res. (2019) 12:135–46. doi: 10.1158/1940-6207.CAPR-17-0289, PMID: PubMed DOI

Bhatt P, Patel M, Thakkar A, Shah U, Patel A, Solanki N, et al. . Chemopreventive role of Phytoconstituents in breast cancer: an integration therapy. Curr Bioact Compd. (2022) 18:2–18. doi: 10.2174/1573407218666211230141836 DOI

Davatgaran-Taghipour Y, Masoomzadeh S, Farzaei MH, Bahramsoltani R, Karimi- Soureh Z, Rahimi R, et al. . Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective. Int J Nanomedicine. (2017) 12:2689–702. doi: 10.2147/IJN.S131973 PubMed DOI PMC

Singh SK, Thakur K, Sharma V, Saini M, Sharma D, Vishwas S, et al. . Exploring the multifaceted potential of chlorogenic acid: journey from nutraceutical to nanomedicine. S Afr J Bot. (2023) 159:658–77. doi: 10.1016/j.sajb.2023.06.038 DOI

Singla M, Gupta S, Porwal O, Binjawhar DN, Sayed AA, Mittal P, et al. . Theoretical design for covering Engeletin with functionalized nanostructure-lipid carriers as neuroprotective agents against Huntington’s disease via the nasal-brain route. Front Pharmacol. (2023) 14:1218625. doi: 10.3389/fphar.2023.1166272, PMID: PubMed DOI PMC

Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta- Torres LS, et al. . Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. (2018) 16:71. doi: 10.1186/s12951-018-0392-8 PubMed DOI PMC

Ud Din F, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, et al. . Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. (2017) 12:7291–309. doi: 10.2147/IJN.S146315 PubMed DOI PMC

Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. (2012) 64:83–101. doi: 10.1016/j.addr.2012.09.021 PubMed DOI

Gumireddy A, Christman R, Kumari D, Tiwari A, North EJ, Chauhan H. Preparation, characterization, and in vitro evaluation of curcumin-and resveratrol-loaded solid lipid nanoparticles. AAPS PharmSciTech. (2019) 20:145. doi: 10.1208/s12249-019-1349-4 PubMed DOI

Fahmy UA. Augmentation of fluvastatin cytotoxicity against prostate carcinoma PC3 cell line utilizing alpha lipoic–ellagic acid nanostructured lipid carrier formula. AAPS PharmSciTech. (2018) 19:3454–61. doi: 10.1208/s12249-018-1199-5, PMID: PubMed DOI

Jiang H, Geng D, Liu H, Li Z, Cao J. Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors. Drug Deliv. (2016) 23:3665–73. doi: 10.1080/10717544.2016.1217954, PMID: PubMed DOI

Mittal P, Vrdhan H, Ajmal G, Bonde G, Kapoor R, Mishra B. Formulation and characterization of genistein-loaded nanostructured lipid carriers: pharmacokinetic, biodistribution and in vitro cytotoxicity studies. Curr Drug Deliv. (2019) 16:215–25. doi: 10.2174/1567201816666181120170137 PubMed DOI

Aditya NP, Shim M, Lee I, Lee Y, Im MH, Ko S. Curcumin and genistein coloaded nanostructured lipid carriers: in vitro digestion and antiprostate cancer activity. J Agric Food Chem. (2013) 61:1878–83. doi: 10.1021/jf305143k, PMID: PubMed DOI

Figueiró F, Bernardi A, Frozza RL, Terroso T, Zanotto-Filho A, Jandrey EH, et al. . Resveratrol-loaded lipid-core nanocapsules treatment reduces in vitro and in vivo glioma growth. J Biomed Nanotechnol. (2013) 9:516–26. doi: 10.1166/jbn.2013.1547, PMID: PubMed DOI

Shrivastava N, Parikh A, Dewangan RP, Biswas L, Verma AK, Mittal S, et al. . Solid self-Nano emulsifying nanoplatform loaded with Tamoxifen and resveratrol for treatment of breast cancer. Pharmaceutics. (2022) 14:1486. doi: 10.3390/pharmaceutics14071486, PMID: PubMed DOI PMC

Stolarczyk EU, Stolarczyk K, Łaszcz M, Kubiszewski M, Maruszak W, Olejarz W, et al. . Synthesis and characterization of genistein conjugated with gold nanoparticles and the study of their cytotoxic properties. Eur J Pharm Sci. (2017) 96:176–85. doi: 10.1016/j.ejps.2016.09.019, PMID: PubMed DOI

Chavva SR, Deshmukh SK, Kanchanapally R, Tyagi N, Coym JW, Singh AP, et al. . Epigallocatechin gallate-gold nanoparticles exhibit superior antitumor activity compared to conventional gold nanoparticles: potential synergistic interactions. Nano. (2019) 9:396. doi: 10.3390/nano9030396, PMID: PubMed DOI PMC

Hussein-Al-Ali SH, Balavandy SK, Abidin ZZ, Kura AU, Fakurazi S, Hussein MZ, et al. . The in vitro therapeutic activity of ellagic acid-alginate-silver nanoparticles on breast cancer cells (MCF-7) and normal fibroblast cells (3T3). Sci Adv Mater. (2016) 8:545–53. doi: 10.1166/sam.2016.2673 DOI

Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. (2018) 103:598–613. doi: 10.1016/j.biopha.2018.04.055, PMID: PubMed DOI

Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm. (2014) 86:7–22. doi: 10.1016/j.ejpb.2013.08.013, PMID: PubMed DOI

Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCS) as drug delivery platform: advances in formulation and delivery strategies. Saudi Pharm J. (2021) 29:999–1012. doi: 10.1016/j.jsps.2021.07.015, PMID: PubMed DOI PMC

Shirodkar RK, Kumar L, Mutalik S, Lewis S. Solid lipid nanoparticles and nanostructured lipid carriers: emerging lipid based drug delivery systems. Pharm Chem J. (2019) 53:440–53. doi: 10.1007/s11094-019-02017-9, PMID: PubMed DOI

Kothamasu P, Kanumur H, Ravur N, Maddu C, Parasuramrajam R, Thangavel S. Nanocapsules: the weapons for novel drug delivery systems. Bioimpacts. (2012) 2:71. doi: 10.5681/bi.2012.011, PMID: PubMed DOI PMC

Nagavarma BVN, Yadav HK, Ayaz AVLS, Vasudha LS, Shivakumar HG. Different techniques for preparation of polymeric nanoparticles-a review. Asian J Pharm Clin Res. (2012) 5:16–23.

Su S, Kang PM. Systemic review of biodegradable nanomaterials in nanomedicine. Nano. (2020) 10:656. doi: 10.3390/nano10040656, PMID: PubMed DOI PMC

Vishwakarma N, Jain A, Sharma R, Mody N, Vyas S, Vyas SP. Lipid- based nanocarriers for lymphatic transportation. AAPS PharmSciTech. (2019) 20:83. doi: 10.1208/s12249-019-1293-3 PubMed DOI

Aswathanarayan JB, Vittal RR. Nanoemulsions and their potential applications in food industry. Front Sustain Food Syst. (2019) 3:95. doi: 10.3389/fsufs.2019.00095 DOI

Huang RF, Wei YJ, Inbaraj BS, Chen BH. Inhibition of colon cancer cell growth by nanoemulsion carrying gold nanoparticles and lycopene. Int J Nanomedicine. (2015) 10:2823–46. doi: 10.2147/IJN.S79107, PMID: PubMed DOI PMC

Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. Biotech. (2015) 5:123–7. doi: 10.1007/s13205-014-0214-0 PubMed DOI PMC

Jeevanandam J, Barhoum A, Chan YS, Dufresne A, Danquah MK. Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol. (2018) 9:1050–74. doi: 10.3762/bjnano.9.98 PubMed DOI PMC

Fan M, Han Y, Gao S, Yan H, Cao L, Li Z, et al. . Ultrasmall gold nanoparticles in cancer diagnosis and therapy. Theranostics. (2020) 10:4944. doi: 10.7150/thno.42471, PMID: PubMed DOI PMC

Roy A, Pandit C, Gacem A, Alqahtani MS, Bilal M, Islam S, et al. . Biologically derived gold nanoparticles and their applications. Bioinorg Chem Appl. (2022) 2022:8184217. doi: 10.1155/2022/8184217 PubMed DOI PMC

Krutyakov YA, Kudrinskiy AA, Olenin AY, Lisichkin GV. Synthesis and properties of silver nanoparticles: advances and prospects. Russ Chem Rev. (2008) 77:233. doi: 10.1070/RC2008v077n03ABEH003751, PMID: PubMed DOI

Slawson RM, Trevors JT, Lee H. Silver accumulation and resistance in Pseudomonas stutzeri. Arch Microbiol. (1992) 158:398–404. doi: 10.1007/BF00205191 DOI

Mikhailov OV, Mikhailova EO. Elemental silver nanoparticles: biosynthesis and bio applications. Materials. (2019) 12:3177. doi: 10.3390/ma12193177, PMID: PubMed DOI PMC

Lang DK, Kaur R, Arora R, Saini B, Arora S. Nitrogen-containing heterocycles as anticancer agents: an overview. Anti Cancer Agents Med Chem. (2020) 20:2150–68. doi: 10.2174/1871520620666200705214917 PubMed DOI

Magne TM, Alencar LMR, Carneiro SV, Fechine LMUD, Fechine PBA, Souza PFN, et al. . Nano-nutraceuticals for health: principles and applications. Rev Bras. (2023) 33:73–88. doi: 10.1007/s43450-022-00338-7, PMID: PubMed DOI PMC

Mukhtar M, Bilal M, Rahdar A, Barani M, Arshad R, Behl T, et al. . Nanomaterials for diagnosis and treatment of brain cancer: recent updates. Chemosensors. (2020) 8:117. doi: 10.3390/chemosensors8040117, PMID: PubMed DOI

Gupta SC, Prasad S, Aggarwal BB. Anti-inflammatory Nutraceuticals and chronic diseases. Cham: Springer; (2016).